March 2026 clinical trial highlights
Clinical trial participants are essential in the quest for new treatments and a cure for pulmonary fibrosis (PF).
Each month, we'll highlight a few of the many trials enrolling volunteers. To view more available trials for various forms of interstitial lung disease (ILD), please visit the 🔍 PFF Clinical Trial Finder.
Seeking participants with ILD
Home-based Pulmonary Rehabilitation and Health Coaching in Patients With ILD
- Study ID: NCT06751069
- Trial Phase: N/A
- Intervention: Pulmonary rehabilitation
- Sponsor: Mayo Clinic
- Study Contact: Johanna Hoult, MS (507.293.1989; hoult.johanna@mayo.edu)
Seeking participants with PF
FIBRONEER™-ON
- Study ID: NCT06238622
- Trial Phase: Phase 3
- Intervention: Oral drug
- Sponsor: Boehringer Ingelheim
- Study Contact: 800.243.0127; clintriage.rdg@boehringer-
ingelheim.com
Resource Spotlight: PFF Community Registry
The PFF Community Registry is a series of surveys for all community members affected by PF or ILD: patients living with PF or ILD, lung transplant recipients who have had PF or ILD, caregivers, and biological family members of patients with PF or ILD, including those who have passed away. We invite eligible participants to join by completing a series of simple surveys. Your survey responses will be used by researchers to better understand how PF and ILD progresses over time, responds to treatments, and how the diseases affect individuals. The more individuals who join and provide responses, the closer we come to a cure. For questions about the PFF Community Registry, contact registry@pulmonaryfibrosis.org |
Putting a face to the science: living with ILD
Kelly's diagnosis of ILD with PF came after a bronchoscopy and lung biopsy following her third hospitalization for pneumonia. As a respiratory therapy student at the time, Kelly struggled to remember what this diagnosis meant and, in the end, there was only one question for her doctor she had: What’s next? Determined to fight the disease, she formed a strong medical team and proactively follows their guidance. In addition to receiving treatment, Kelly participated in a clinical trial. While she initially viewed clinical trials as "unknown territory," she decided to proceed after thorough education and evaluation. She located her trial using the PFF Clinical Trial Finder. Kelly characterized the experience as both seamless and rewarding, highlighting the passionate individuals she met, the insight and empowerment she gained, and the value of contributing to future PF research and therapies. Kelly found additional insight and purpose through an optimistic attitude, prayer, and reflection. She found support and resources through the PFF. Today, Kelly is a PFF Ambassador, raising awareness and educating others about ILD and PF. To learn more about recruiting clinical trials, visit the PFF Clinical Trial Finder. |
 |
PFF CTI Webinar Series February and June 2026
The PFF Clinical Trial Innovation (CTI) Webinar Series was held on February 11, 2026. We appreciate the community’s participation in our discussion regarding the development of innovative therapies and recent advancements in PF and ILD research.
To learn more about the FOCUSIPF, AURORA, and ASPIRE-IPF clinical trials discussed during the February webinar, watch the recording here: PFF Clinical Trial Innovation (CTI) Webinar: New Advances in PF & ILD Research.
Our next PFF CTI Webinar Series will be held on Tuesday, June 23, 2026, from noon to 1:00 p.m. CT. The June webinar will feature three different studies, and you can register for the webinar now.
Deupirfenidone (LYT-100) receives orphan drug approval
Orphan drug designation is a pathway the US Food and Drug Administration (FDA) has to support the development and evaluation of new treatments for rare diseases, such as IPF. The FDA has authority to grant orphan drug designation to a drug or biological product to prevent, diagnose, or treat a rare disease or condition.
In February 2026, the FDA granted PureTech's investigational therapy, deupirfenidone, orphan drug designation. PureTech completed the phase 2b study, ELEVATE IPF, showing participants taking deupirfenidone had less decline in lung function when compared to participants taking currently approved therapy pirfenidone. PureTech now intends to initiate the phase 3 SURPASS-IPF in the first half of 2026 to further test deupirfenidone.
In the U.S., a rare disease is considered a condition which affects fewer than 200,000 people across the country. The orphan drug designation illustrates there is still a significant unmet need for patients living with IPF.
|
If you have any questions or comments about this newsletter, please email partnerships@